ApoRx Biopharmaceuticals
Targeted Protein Degradation Drug Discovery
Company Overview
Snapshot
Founded in January 2021 by Avishai Levy, Omri Erez, Philippe Nakache, and Orna Harel, ApoRx Biopharmaceuticals operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on drug discovery.
Business overview
ApoRx Biopharmaceuticals is a drug-discovery company specializing in the identification, design, characterization, and development of small proteolysis-targeting molecules. The company aims to harness the intracellular ubiquitin-proteasome machinery to degrade disease-causing proteins, particularly in oncology and other indications. Its core technology is built around the Aperion library, a proprietary collection of RING E3 ligase binders. ApoRx operates within the Health Tech & Life Sciences sector, with a focus on pharmaceuticals, biotechnology, and cancer therapy.
Company Intelligence Q&A
- When was ApoRx Biopharmaceuticals founded?
- ApoRx Biopharmaceuticals was founded in January 2021.
- Who are the founders of ApoRx Biopharmaceuticals?
- The company was founded by Avishai Levy, Omri Erez, Philippe Nakache, and Orna Harel.
- What is ApoRx Biopharmaceuticals' primary focus?
- ApoRx Biopharmaceuticals focuses on targeted protein degradation drug discovery, specifically developing small molecules to degrade disease-causing proteins in cancer and other indications.
- What is the core technology of ApoRx Biopharmaceuticals?
- The core technology of ApoRx Biopharmaceuticals is the Aperion library, a proprietary focus library of RING E3 ligase binders designed to utilize the ubiquitin-proteasome machinery for targeted protein degradation.
- What industry sector does ApoRx Biopharmaceuticals operate in?
- ApoRx Biopharmaceuticals operates primarily within the Health Tech & Life Sciences sector, with a specific focus on pharmaceuticals and biotechnology.